Challenges to Initiate and Complete a 4-month Rifapentine-moxifloxacin TBTreatment Regimen.

Details

• Alternative Title:
  The International Journal of Tuberculosis and Lung Disease: the Official Journal of the International Union Against Tuberculosis and Lung Disease, 2025, v. 29, no. 7: Challenges to Initiate and Complete a 4-month Rifapentine-moxifloxacin TBTreatment Regimen.
• Journal Article:
  The International Journal of Tuberculosis and Lung Disease: the Official Journal of the International Union Against Tuberculosis and Lung Disease
• Personal Author:
  Galvis, M.E. ; Gao, G.E. ; Salerno, M.M. ; Whitehead, M. ; Juste, D. ; Buchanan, C. ; Chuck, C. ; Iskhakova, F. ; Macaraig, M. ; Dworkin, F. ; Burzynski, J. ; Nilsen, D.
• Description:
  In February 2022, the U.S. Centers for Disease Control and Prevention (CDC) recommended a 4-month rifapentine-moxifloxacin based regimen (4-HPMZ) for treating drug-susceptible pulmonary TB. We describe 4-HPMZ implementation, treatment outcomes, and regimen tolerability at New York City (NYC) Health Department TB clinics.A multidisciplinary workgroup developed a 4-HPMZ implementation plan and protocol based on CDC patient eligibility guidance. Treatment outcomes were classified as 'completed' when 4-HPMZ was completed within 5 months or 'discontinued' when 4-HPMZ was stopped due to clinical or programmatic reasons. Adverse events (AEs) included abnormal lab results, or any medication-related concern reported by patients.Between April 2022 to December 2023, 617 patients with TB visited NYC Health Department TB clinics; for 4-HPMZ, 333 (54%) were ineligible and 284 (46%) were eligible. Of the eligible patients, 40 (14%) were prescribed 4-HPMZ; of these, 36 initiated 4-HPMZ treatment, 13 (36%) completed treatment, and 23 (64%) discontinued. A total of 15 patients (42%) discontinued due to AEs.Significant programmatic and clinical challenges were associated with initiation and completion of 4-HPMZ treatment. As a result, few patients completed treatment. Further assessment is needed to identify populations most likely to initiate and complete 4-HPMZ..
• Content Notes:
  Author manuscript
• Subjects:
  • Humans
  • Antitubercular Agents
  • Rifampin
  • Male
  • Female
  • Tuberculosis, Pulmonary
  • Treatment Outcome
  • Adult
  • Middle Aged
  • Centers for Disease Control and Prevention, U.S.
  More +
• Keywords:
  • Mycobacterium tuberculosis
  • treatment
  • public health
  • New York City
  • USA
  • tuberculosis
• Source:
  The International Journal of Tuberculosis and Lung Disease: the Official Journal of the International Union Against Tuberculosis and Lung Disease, 2025, v. 29, no. 7
• DOI:
  https://doi.org/10.5588/ijtld.24.0616
• ISSN:
  1027-3719 ; 1815-7920
• Pubmed ID:
  40579760
• Pubmed Central ID:
  PMC12233099
• Document Type:
  Text
• Funding:
  CC999999/ImCDC/Intramural CDC HHSUnited States/
• Genre:
  Journal Article
• Place as Subject:
  New York City ; United States
• Pages in Document:
  318-324 (14 pdf pages)
• Volume:
  29
• Issue:
  7
• Download URL:
  https://stacks.cdc.gov/view/cdc/261297/cdc_261297_DS1.pdf
• File Type:
  [PDF - 392.00 KB]
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha-512:424c40ff06620c09b726d4f4470fe52abd20b973d3efd583737cdae7a59a0aedae5252537f2f3b47b3ac46537e3557cdf8ce380ac48f33eeeab529fe1b0d3e24